Therapeutics and Clinical Risk Management最新文献

筛选
英文 中文
The Etiologic Landscape of Lymphoproliferation in Childhood: Proposal for a Diagnostic Approach Exploring from Infections to Inborn Errors of Immunity and Metabolic Diseases 儿童淋巴细胞增生的病因:从感染到先天性免疫错误和代谢性疾病的诊断方法探索建议
IF 2.8 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2024-05-01 DOI: 10.2147/tcrm.s462996
Giorgio Costagliola, Emanuela De Marco, Francesco Massei, Giulia Roberti, Fabrizio Catena, Gabriella Casazza, Rita Consolini
{"title":"The Etiologic Landscape of Lymphoproliferation in Childhood: Proposal for a Diagnostic Approach Exploring from Infections to Inborn Errors of Immunity and Metabolic Diseases","authors":"Giorgio Costagliola, Emanuela De Marco, Francesco Massei, Giulia Roberti, Fabrizio Catena, Gabriella Casazza, Rita Consolini","doi":"10.2147/tcrm.s462996","DOIUrl":"https://doi.org/10.2147/tcrm.s462996","url":null,"abstract":"","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141041526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging Treatment Options for Myelofibrosis: Focus on Anemia. 骨髓纤维化的新兴治疗选择:关注贫血。
IF 2.8 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2023-06-28 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S386802
Dahniel Sastow, Douglas Tremblay
{"title":"Emerging Treatment Options for Myelofibrosis: Focus on Anemia.","authors":"Dahniel Sastow,&nbsp;Douglas Tremblay","doi":"10.2147/TCRM.S386802","DOIUrl":"10.2147/TCRM.S386802","url":null,"abstract":"<p><p>Myelofibrosis (MF) is a hematologic malignancy characterized by abnormal proliferation of myeloid cells and the release of pro-inflammatory cytokines, leading to progressive bone marrow dysfunction. The introduction of ruxolitinib just over a decade ago marked a significant advancement in MF therapy, with JAK inhibitors now being the first-line treatment for reducing spleen size and managing symptoms. However, early JAK inhibitors (ruxolitinib and fedratinib) are often associated with cytopenias, particularly thrombocytopenia and anemia, which limit their tolerability. To address these complications, pacritinib has been developed and recently approved for patients with thrombocytopenia, while momelotinib is in development for those with anemia. Although JAK inhibitors have significantly improved the quality of life of MF patients, they have not demonstrated the ability to reduce leukemic transformation and their impact on survival is debated. Numerous drugs are currently being developed and investigated in clinical trials, both as standalone therapy and in combination with JAK inhibitors, with promising results enhancing the benefits of JAK inhibitors. In the near future, MF treatment strategies will involve selecting the most suitable JAK inhibitor based on individual patient characteristics and prior therapy. Ongoing and future clinical trials are crucial for advancing the field and expanding therapeutic options for MF patients.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/b4/tcrm-19-535.PMC10315142.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Affecting Radial Artery Occlusion After Right Transradial Artery Catheterization for Coronary Intervention and Procedures. 右侧经桡动脉导管冠状动脉介入和手术后桡动脉闭塞的影响因素。
IF 2.3 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2023-06-24 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S403410
Dujuan Xu, Ying Liu, Chao Xu, Xuekui Liu, Ye Chen, Chunguang Feng, Nan Lyu
{"title":"Factors Affecting Radial Artery Occlusion After Right Transradial Artery Catheterization for Coronary Intervention and Procedures.","authors":"Dujuan Xu, Ying Liu, Chao Xu, Xuekui Liu, Ye Chen, Chunguang Feng, Nan Lyu","doi":"10.2147/TCRM.S403410","DOIUrl":"10.2147/TCRM.S403410","url":null,"abstract":"<p><strong>Objective: </strong>To determine the factors influencing proximal radial artery occlusion (PRAO) right radial artery after coronary intervention.</p><p><strong>Methods: </strong>This is a single-center prospective observational study. A total of 460 patients were selected to undergo coronary angiography (CAG) or percutaneous coronary intervention (PCI) via the proximal transradial approach (PTRA) or distal transradial approach (DTRA). The 6F sheath tube were received by all patients. Radial artery ultrasound was performed 1 day before procedure and 1-4 days after procedure. Patients were divided into the PRAO group (42 cases) and the non-PRAO group (418 cases). General clinical data and preoperative radial artery ultrasound indexes of the two groups were compared to analyze related factors leading to PRAO.</p><p><strong>Results: </strong>The total incidence of PRAO was 9.1%, including 3.8% for DTAR and 12.7% for PTRA. The PRAO rate of DTRA was significantly lower than that of PTRA (<i>p</i> < 0.05). Female, low body weight, low body mass index (BMI) and CAG patients were more likely to develop PRAO after procedure (<i>p</i> < 0.05). The internal diameter and cross-sectional area of the distal radial artery and proximal radial artery were smaller in the PRAO group than in the non-PRAO group, and the differences were statistically significant (<i>p</i> < 0.05). Multifactorial model analysis showed that the puncture approach, radial artery diameter and procedure type were predictive factors of PRAO, and the receiver operating characteristic curve showed a good predictive value.</p><p><strong>Conclusion: </strong>A larger radial artery diameter and DTRA may reduce the incidence of PRAO. Preoperative radial artery ultrasound can guide the clinical selection of appropriate arterial sheath and puncture approach.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/e3/tcrm-19-525.PMC10305768.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9737563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Tricalcium Phosphate on Healing of Non-Unions: An Observational Study of over 400 Non-Unions. 磷酸三钙对非溃疡愈合的影响:对 400 多例非溃疡患者的观察研究。
IF 2.3 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2023-05-12 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S409119
Thomas Ferbert, Christina Münch, Sebastian Findeisen, William Pauly, Matthias Miska, Tobias Grossner, Michael C Tanner, Gerhard Schmidmaier, Lars Helbig
{"title":"Effect of Tricalcium Phosphate on Healing of Non-Unions: An Observational Study of over 400 Non-Unions.","authors":"Thomas Ferbert, Christina Münch, Sebastian Findeisen, William Pauly, Matthias Miska, Tobias Grossner, Michael C Tanner, Gerhard Schmidmaier, Lars Helbig","doi":"10.2147/TCRM.S409119","DOIUrl":"10.2147/TCRM.S409119","url":null,"abstract":"<p><strong>Purpose: </strong>A central aspect of the treatment of non-unions is the filling of bone defects. The quantity of available autologous bone for this purpose is limited. Alternatively, or additionally, bone substitutes may be used. The aim of this retrospective, single-center study including 404 non-unions in 393 patients is to investigate the effect of tricalcium phosphate (TCP) on the healing of non-unions. Furthermore, the influence of gender, age, smoking status, comorbidities, type of surgical procedure, presence of infection, and length of treatment was investigated.</p><p><strong>Methods: </strong>We evaluated three groups of patients. Group 1 received TCP + BG, group 2 received BG alone and group 3 received no augmentation. Bone stability was assessed 1 and 2 years after non-union revision surgery through analysis of radiographs using the Lane Sandhu Score. Scores ≥3 were rated as stable Other influencing factors were collected from the electronic medical record.</p><p><strong>Results: </strong>In 224 non-unions, bone defects were filled with autologous bone and TCP (TCP+BG). In 137 non-unions, bone defects were filled with autologous bone (BG), and in 43 non-unions presenting non-relevant defects, neither autologous bone nor TCP were used (NBG). After 2 years, 72.7% of the TCP+BG patients, 90.1% of the BG patients and 84.4% of the NBG patients achieved a consolidation score ≥3. Advanced age, presence of comorbidities and longer treatment period had a significantly negative effect on consolidation 1 year after surgery. Longer treatment periods also showed a negative significant effect after 2 years. It is notable that larger defects, mainly treated with the combination of autologous bone and TCP, showed similar healing rates to that of smaller defects after 2 years.</p><p><strong>Conclusion: </strong>The combination of TCP and autologous bone-grafts shows good results in the reconstruction of complicated bone-defects, but patience is required since the healing period exceeds 1 year in most patients.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/1f/tcrm-19-395.PMC10187654.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9490166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discontinuation of Antidepressants in Older Adults: A Literature Review. 老年人停用抗抑郁药:文献综述。
IF 2.3 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2023-03-28 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S395449
Ahmed Romdhani, Stephanie Lehmann, Joël Schlatter
{"title":"Discontinuation of Antidepressants in Older Adults: A Literature Review.","authors":"Ahmed Romdhani, Stephanie Lehmann, Joël Schlatter","doi":"10.2147/TCRM.S395449","DOIUrl":"10.2147/TCRM.S395449","url":null,"abstract":"<p><p>Polypharmacy increases the risk of unbearable side effects, drug-drug interactions, and hospitalizations in geriatric patients. The iatrogenic risk of inadequate management of antidepressants is very important in this population. Therefore, primary care physicians and geriatricians have the responsibility of the optimization of antidepressants prescriptions. Our work is a literature review of the European and the international guidelines regarding the management of antidepressants. We reviewed the PubMed database and Google scholar for articles and reviews from 2015. We also screened relevant articles for more references and searched the web for available European guidelines relevant to our topic. We divided our findings into four main inquiries that are Indication, effectiveness, tolerability, and iatrogenic risks. Poor or absence of effectiveness should lead to a readjustment of the treatment plan. In case of unbearable side effects, antidepressants should be stopped, and alternative non-pharmacological therapies should be proposed. Doctors should look out for drug-drug interaction risks in this population and constantly adjust the prescription. Prescription of antidepressants is not always evidence based which leads to heavy iatrogenic consequences. We suggest a simple 4-questions-algorithm that aims to remind doctors of the basics of good practice and helps in the process of deprescribing an antidepressant in older adults.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/2a/tcrm-19-291.PMC10066696.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9248514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive Value of Preoperative Diffusion Tensor Imaging for Evaluating Postoperative Outcomes of Supratentorial Glioma in the Motor Function Area. 术前弥散张量成像对评估运动功能区脑室上胶质瘤术后疗效的预测价值
IF 2.3 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2023-03-14 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S402622
Nguyen Duy Hung, Nguyen Duy Linh, Nguyen Ha Vi, Nguyen Thi Van Anh, Nguyen Dinh Hieu, Duong Dai Ha, Nguyen Minh Duc
{"title":"Predictive Value of Preoperative Diffusion Tensor Imaging for Evaluating Postoperative Outcomes of Supratentorial Glioma in the Motor Function Area.","authors":"Nguyen Duy Hung, Nguyen Duy Linh, Nguyen Ha Vi, Nguyen Thi Van Anh, Nguyen Dinh Hieu, Duong Dai Ha, Nguyen Minh Duc","doi":"10.2147/TCRM.S402622","DOIUrl":"10.2147/TCRM.S402622","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the predictive value of preoperative diffusion tensor imaging (DTI) data for surgical outcomes of patients with supratentorial glioma in the motor function area.</p><p><strong>Patients and methods: </strong>This is a retrospective study of 43 patients receiving navigation-guided surgery for histopathologically demonstrated supratentorial glioma in the motor function area. All patients underwent preoperative 3 Tesla magnetic resonance imaging examinations with conventional and DTI sequences. Data on preoperative imaging and pre- and postoperative clinical characteristics of patients were retrospectively collected. Univariate and multivariate linear regressions were applied to analyze the relationships between preoperative parameters and pre- and postoperative muscle strength and the Karnofsky Performance Status (KPS) score.</p><p><strong>Results: </strong>Fourteen patients had low-grade gliomas and 29 had high-grade gliomas. Although the corticospinal tract (CST) score did not differ significantly between tumor grades, edema and deviation were common in low-grade gliomas (64.3%), while destroyed and infiltrated lesions were common in high-grade gliomas (58.6%). Muscle strength improved after surgery in the deviated tract group (40%) more than in the infiltrated tract group (33.3%). Two independent indices, preoperative muscle strength (<i>p</i> = 0.000) and glioma-to-CST distance (<i>p</i> = 0.001), were linearly related to postoperative muscle strength. The preoperative KPS score was the only indicator that affected the postoperative KPS score (<i>p</i> = 0.000).</p><p><strong>Conclusion: </strong>DTI should be considered in surgical management of supratentorial gliomas in the motor function area to determine the appropriate surgical strategy and predict the nature of the tumor and postoperative motor function.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/86/tcrm-19-269.PMC10024488.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9156229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA AFAP1-AS1 Induces Gefitinib Resistance of Lung Adenocarcinoma Through the miR-653-5p/AGR2 Axis. LncRNA AFAP1-AS1 通过 miR-653-5p/AGR2 轴诱导吉非替尼对肺腺癌的耐药性
IF 2.3 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2023-01-05 eCollection Date: 2023-01-01 DOI: 10.2147/TCRM.S374162
Tao Zuo, Ping Jiang, Jun Fu, Yongjian Zhang
{"title":"LncRNA AFAP1-AS1 Induces Gefitinib Resistance of Lung Adenocarcinoma Through the miR-653-5p/AGR2 Axis.","authors":"Tao Zuo, Ping Jiang, Jun Fu, Yongjian Zhang","doi":"10.2147/TCRM.S374162","DOIUrl":"10.2147/TCRM.S374162","url":null,"abstract":"<p><strong>Purpose: </strong>Gefitinib resistance limits the therapeutic efficacy of gefitinib to lung adenocarcinoma (LUAD). The goal of this research is to learn more about the lncRNA AFAP1-AS1 and how it functions in gefitinib-resistant LUAD cells.</p><p><strong>Methods: </strong>RT-qPCR was performed to test the expression of AFAP1-AS1, miR-653-5p and AGR2 in LUAD tissues with acquired resistance to gefitinib or not as well as in gefitinib-resistant LUAD cells. Cell proliferation, invasion and apoptosis were measured by CCK8 assays, transwell invasion assays and flow cytometry, respectively. Luciferase reporter assay showed that miR-653-5p and AFAP1-AS1 or AGR2 interactions.</p><p><strong>Results: </strong>In gefitinib-resistant LUAD cells and tissues, AFAP1-AS1 was overexpressed. Meanwhile, silencing AFAP1-AS1 reduced proliferation and migration while increasing apoptosis and gefitinib sensitivity. Mechanically, AFAP1-AS1 sequestered the miR-653-5p and blocked the inhibition of miR-653-5p to AGR2 and stepwise upregulated AGR2 overexpression in LUAD gefitinib resistant cells, resulting gefitinib resistance in LUAD.</p><p><strong>Conclusion: </strong>AFAP1-AS1 promotes gefitinib-resistance LUAD cells through a previously unrecognized miR-653-5p/AGR2 axis, suggesting targeting AFAP1-AS1/miR-653-5p/AGR2 axis might be a promising way for LUAD intervention.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/50/tcrm-19-1.PMC9829986.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10527573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Safety of Oral Rehydration Solution Jelly for Water and Electrolyte Intake in Patients with Dysphagia. 口服补液果冻用于吞咽困难患者饮水和电解质摄入的安全性。
IF 2.8 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S398281
Kazuharu Nakagawa, Kanako Yoshimi, Akira Yoshizawa, Kota Aritaki, Kohei Yamaguchi, Ayako Nakane, Haruka Tohara
{"title":"The Safety of Oral Rehydration Solution Jelly for Water and Electrolyte Intake in Patients with Dysphagia.","authors":"Kazuharu Nakagawa,&nbsp;Kanako Yoshimi,&nbsp;Akira Yoshizawa,&nbsp;Kota Aritaki,&nbsp;Kohei Yamaguchi,&nbsp;Ayako Nakane,&nbsp;Haruka Tohara","doi":"10.2147/TCRM.S398281","DOIUrl":"https://doi.org/10.2147/TCRM.S398281","url":null,"abstract":"<p><strong>Purpose: </strong>Oral rehydration solutions (ORSs) are effective in replacing fluids and electrolytes and are widely used. OS-1 Jelly (Otsuka Pharmaceutical Factory, Tokushima, Japan) is a jelly drink corresponding to code 2-1 of the 2021 Japanese Dysphagia Diet. Although jelly drinks are less likely to be aspirated than liquids, their physical properties vary depending on the product. Therefore, the severity of dysphagia may affect intake status. This study aimed to investigate the association between the intake status of ORS jelly and swallowing function.</p><p><strong>Patients and methods: </strong>Thirty-six patients with dysphagia who required videoendoscopic swallowing evaluation at our university hospital were enrolled. Videoendoscopic swallowing evaluation was performed, and each participant swallowed 5 mL of OS-1 Jelly or thickened water modified to International Dysphagia Diet Standardization Initiative (IDDSI) level 2 three times. Statistical analysis was performed to determine the difference in the number of swallows, time until the swallowing reflex, position for inducing the swallowing reflex, presence of pharyngeal residue, penetration, or aspiration between ORS jelly and thickened water.</p><p><strong>Results: </strong>The time until the swallowing reflex was induced and the position of the swallowing reflex triggered were significantly earlier for ORS jelly (<i>p</i>=0.012, <i>p</i>=0.001). The incidence of pharyngeal residue was significantly lower with ORS jelly (<i>p</i>=0.002). The Penetration-Aspiration Scale score was similar for both samples (<i>p</i>=0.062), and no aspiration was observed in either sample.</p><p><strong>Conclusion: </strong>Patients with dysphagia who can swallow thickened water modified to IDDSI level 2 can consume ORS jelly. ORS jelly, which requires no thickening and can be easily and safely consumed, is effective for water and electrolyte intake in patients with dysphagia.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/fd/tcrm-19-219.PMC10010143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9122063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy. Palbociclib + Fulvestrant与Ribociclib + Fulvestrant和Abemaciclib + Fulvestrant在意大利治疗内分泌耐药晚期或转移性乳腺癌的经济评价
IF 2.8 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S391769
Giorgio Lorenzo Colombo, Maria Chiara Valentino, Alessandra Fabi, Maria Vittoria Dieci, Mauro Caruggi, Giacomo Matteo Bruno, Gloria Lombardi, Sergio Di Matteo
{"title":"Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy.","authors":"Giorgio Lorenzo Colombo,&nbsp;Maria Chiara Valentino,&nbsp;Alessandra Fabi,&nbsp;Maria Vittoria Dieci,&nbsp;Mauro Caruggi,&nbsp;Giacomo Matteo Bruno,&nbsp;Gloria Lombardi,&nbsp;Sergio Di Matteo","doi":"10.2147/TCRM.S391769","DOIUrl":"https://doi.org/10.2147/TCRM.S391769","url":null,"abstract":"<p><strong>Background: </strong>To date, no study evaluated the cost-effectiveness of palbociclib (PAL) plus fulvestrant (FUL) vs ribociclib (RIB) plus FUL and abemaciclib (ABM) plus FUL in Italy. Cost-effectiveness analysis comparing the three cyclin-dependent 4/6 kinase inhibitors in combination with endocrine therapies for the management of postmenopausal women with HR+, HER2- advanced or metastatic breast cancer in Italy was developed.</p><p><strong>Material and methods: </strong>To assess the cost-effectiveness of PAL plus FUL vs RIB plus FUL and ABM plus FUL, a cost-minimization has been carried out with a conservative scenario considering three CDK4/6 inhibitors with equal effectiveness in terms of overall survival (OS) (MAIC, Rugo et al 2021). Adverse events (AEs) associated with all therapies were obtained from clinical trials. Ad-hoc analysis was performed to estimate the cost-effectiveness considering the quality-of-life (QoL) data (Lloyd et al 2006).</p><p><strong>Results: </strong>Cost-minimization inputs were drugs, visits and exams, AE monitoring and best supportive care (BSC) before the progression state, active and BSC in the progression and terminal phase of the last two weeks of life. Given the comparability of PAL, RIB and ABM in terms of efficacy, this analysis demonstrated slight economic savings over a lifetime for PAL. Results showed saving per patient of €305 (lifetime) when PAL is compared with RIB; for PAL vs ABM a saving of €243 (lifetime) in a conservative scenario. Results of a budget impact analysis showed a potential savings of €319,563 for PAL vs RIB and €297,544 for PAL vs ABM. When QoL data were considered, results may favor PAL due to the lower impact of AE with savings and improvement in the QoL related to fewer AE.</p><p><strong>Conclusion: </strong>From the Italian perspective, a cost-saving profile associated with the use of PAL+FUL for the management of advanced/metastatic HR+/HER2- breast cancer compared to RIB+FUL and ABM+FUL emerged.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/33/tcrm-19-301.PMC10066701.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9248508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Safety and Efficacy of Liver Venous Deprivation Following Transarterial Chemoembolization Before Major Hepatectomy for Hepatocellular Carcinoma. 肝细胞癌大肝切除术前经动脉化疗栓塞后肝静脉剥夺的安全性和有效性。
IF 2.8 3区 医学
Therapeutics and Clinical Risk Management Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S411080
Than-Van Sy, Le Thanh Dung, Bui-Van Giang, Nguyen Quang Nghia, Ninh Viet Khai, Cao Manh Thau, Pham Gia Anh, Trinh Hong Son, Nguyen Minh Duc
{"title":"Safety and Efficacy of Liver Venous Deprivation Following Transarterial Chemoembolization Before Major Hepatectomy for Hepatocellular Carcinoma.","authors":"Than-Van Sy,&nbsp;Le Thanh Dung,&nbsp;Bui-Van Giang,&nbsp;Nguyen Quang Nghia,&nbsp;Ninh Viet Khai,&nbsp;Cao Manh Thau,&nbsp;Pham Gia Anh,&nbsp;Trinh Hong Son,&nbsp;Nguyen Minh Duc","doi":"10.2147/TCRM.S411080","DOIUrl":"https://doi.org/10.2147/TCRM.S411080","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the safety and efficacy of liver venous deprivation (LVD) following transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>Between January 2021 and December 2022, HCC patients indicated for hepatectomy with initial insufficient future liver remnant (FLR) underwent LVD after TACE to induce preoperative liver hypertrophy.</p><p><strong>Results: </strong>Twenty-seven HCC patients with a median age of 55 years underwent LVD. No TACE or LVD procedure-associated complications occurred, except for 1 case presenting with grade A liver failure after LVD (then recovered after 7 days). The FLR volume was 29.3% (interquartile range [IQR] = 7.5) and 48.9% (IQR = 8.6) of the total liver volume before and after LVD, respectively (p < 0.001). The degree of hypertrophy and FLR hypertrophy rate were 14.8% (IQR = 8.4) and 55.2% (IQR = 36.7), respectively. All 27 patients demonstrated sufficient FLR after LVD (24 patients at three weeks post-LVD, one at six weeks, and two at ten weeks), but only 21 patients accepted surgery. Postoperative histopathology showed 16 patients with cirrhosis and five with mild fibrosis (F1, F2). One patient presented with severe intraoperative bleeding due to damage of left hepatic vein and developed grade C liver failure, then died on day 32 postoperation.</p><p><strong>Conclusion: </strong>LVD following TACE seems to be a safe, effective, and feasible method of inducing significant FLR regeneration in HCC, even in well-selected cirrhotic livers. Comparative studies with a large patient population and multicenter data are needed for further evaluation.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/33/tcrm-19-425.PMC10202697.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9896923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信